IRLAB A — IRLAB Therapeutics AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK128.26m
- SEK76.35m
- SEK57.46m
Annual cashflow statement for IRLAB Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 52.6 | -113 | -181 | -75.1 | -93.4 |
| Depreciation | |||||
| Non-Cash Items | 41.8 | 4.48 | 7.24 | -4.06 | -3.57 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 34.3 | -34 | 8.67 | 9 | 41.7 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 129 | -143 | -165 | -65.6 | -55.2 |
| Capital Expenditures | -0.708 | -2.88 | -0.293 | -0.199 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -0.5 | 0 | — | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -0.708 | -3.38 | -0.293 | -0.199 | 0 |
| Financing Cash Flow Items | — | — | — | — | -0.001 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3.04 | -3.13 | 23.7 | 21.4 | 73.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 125 | -149 | -141 | -44.4 | 14.9 |